A LITERATURE REVIEW ON THE ROLE OF ADIPOCYTOKINES IN BREAST CANCER AND METABOLIC SYNDROME
DOI:
https://doi.org/10.22159/ajpcr.2025v18i9.55371Keywords:
Adipocytokines, Breast cancer, Metabolic syndrome, Obesity, Inflammation, Insulin resistanceAbstract
Adipocytokines, bioactive molecules secreted by adipose tissue, have emerged as critical regulators of physiological processes and key contributors to the pathogenesis of various diseases. The relationship between adipocytokines, breast cancer (BC), and metabolic syndrome (MetS) represents a complex network involving intricate signaling pathways, such as those governing inflammation, insulin resistance, and angiogenesis. Understanding the dual role of specific adipocytokines in both promoting and inhibiting BC progression, while also influencing MetS development, provides valuable insights. This review synthesizes current literature, illuminating the molecular mechanisms underlying these associations, highlighting their potential as biomarkers and therapeutic targets, and emphasizing the need for integrated strategies to manage the interconnected risks of BC and MetS. Further research focusing on specific BC subtypes and longitudinal studies is crucial for translating these findings into clinical practice.
Downloads
References
1. Naif NH, Ahmed EM, Thamer NA, Muhsein OA. The impact of inflammatory and adipokine biomarkers on breast cancer progression and patient outcomes. Bull Pharm Sci Assiut Univ. 2025 Jun 1;48(1):511-22. doi: 10.21608/bfsa.2025.339732.2360
2. Habanjar O, Bingula R, Decombat C, Diab-Assaf M, Caldefie-Chezet F, Delort L. Crosstalk of inflammatory cytokines within the breast tumor microenvironment. Int J Mol Sci. 2023 Feb 16;24(4):4002. doi: 10.3390/ijms24044002, PMID 36835413, PMCID PMC9964711
3. Ghadge AA, Khaire AA. Leptin as a predictive marker for metabolic syndrome. Cytokine. 2019 Sep;121:154735. doi: 10.1016/j. cyto.2019.154735, PMID 31154250
4. Verras GI, Tchabashvili L, Chlorogiannis DD, Mulita F, Argentou MI. Updated clinical evidence on the role of adipokines and breast cancer: A review. Cancers (Basel). 2023 Mar 3;15(5):1572. doi: 10.3390/ cancers15051572, PMID 36900364, PMCID PMC10000674
5. Koprivčić I, Marjanović K, Matić A, Tolušić Levak M, Lovrić I, Pauzar B, et al. Serum leptin level in breast cancer. Acta Clin Croat. 2022 Mar;61(1):79-85. doi: 10.20471/acc.2022.61.01.10, PMID 36398078, PMCID PMC9616027
6. Obi N, Jung AY, Maurer T, Huebner M, Johnson T, Behrens S, et al. Association of circulating leptin, adiponectin, and resistin concentrations with long-term breast cancer prognosis in a German patient cohort. Sci Rep. 2021 Dec 7;11(1):23526. doi: 10.1038/s41598- 021-02958-w, PMID 34876619, PMCID PMC8651788
7. Güven HE, Doğan L, Gülçelik MA, Gülçelik NE. Adiponectin: A predictor for breast cancer survival? Eur J Breast Health. 2019;15(1):13-7. doi: 10.5152/ejbh.2018.4349, PMID 30816355, PMCID PMC6385722
8. Zhao C, Wu M, Zeng N, Xiong M, Hu W, Lv W, et al. Cancer-associated adipocytes: emerging supporters in breast cancer. J Exp Clin Cancer Res. 2020 Aug 12;39(1):156. doi: 10.1186/s13046-020-01666-z, PMID 32787888, PMCID PMC7425140
9. Nehme R, Diab-Assaf M, Decombat C, Delort L, Caldefie-Chezet F. Targeting adiponectin in breast cancer. Biomedicines. 2022 Nov 17;10(11):2958. doi: 10.3390/biomedicines10112958, PMID 36428526, PMCID PMC9687473
10. Kim JW, Kim JH, Lee YJ. The role of adipokines in tumor progression and its association with obesity. Biomedicines. 2024 Jan 3;12(1):97. doi: 10.3390/biomedicines12010097, PMID 38255203
11. Zhang J, Lu E, Deng L, Zhu Y, Lu X, Li X, et al. Immunological roles for resistin and related adipokines in obesity-associated tumors. Int Immunopharmacol. 2024 Dec 5;142(A):112911. doi: 10.1016/j. intimp.2024.112911, PMID 39232363
12. Mir MM, Mir R, Alghamdi MA, Wani JI, Sabah ZU, Jeelani M, et al. Differential association of selected adipocytokines, adiponectin, leptin, resistin, visfatin and chemerin, with the pathogenesis and progression of type 2 diabetes mellitus (T2DM) in the Asir Region of Saudi Arabia: A case control study. J Pers Med. 2022 May 1;12(5):735. doi: 10.3390/ jpm12050735, PMID 35629157, PMCID PMC9143828
13. Rajput PK, Sharma JR, Yadav UC. Cellular and molecular insights into the roles of visfatin in breast cancer cells plasticity programs. Life Sci. 2022 Sep 1;304:120706. doi: 10.1016/j.lfs.2022.120706, PMID 35691376
14. Alim LF, Keane C. Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment. Curr Opin Immunol. 2024 Feb;86:102409. doi: 10.1016/j.coi.2023.102409, 2023 Dec 27. PMID 38154421
15. Zhang K, Chen L, Zheng H, Zeng Y. Cytokines secreted from adipose tissues mediate tumor proliferation and metastasis in triple negative breast cancer. BMC Cancer. 2022 Aug 13;22(1):886. doi: 10.1186/ s12885-022-09959-6, PMID 35964108, PMCID PMC9375239
16. Atoum MF, Alzoughool F, Al-Hourani H. Linkage between obesity leptin and breast cancer. Breast Cancer (Auckl). 2020 Jan 10;14:1178223419898458. doi: 10.1177/1178223419898458, PMID 31975779, PMCID PMC6956603
17. Naimo GD, Paolì A, Giordano F, Forestiero M, Panno ML, Andò S, et al. Unraveling the role of adiponectin receptors in obesity-related breast cancer. Int J Mol Sci. 2023 May 17;24(10):8907. doi: 10.3390/ ijms24108907, PMID 37240258, PMCID PMC10218957
18. Cairat M, Rinaldi S, Navionis AS, Romieu I, Biessy C, Viallon V, et al. Circulating inflammatory biomarkers, adipokines and breast cancer risk-a case-control study nested within the EPIC cohort. BMC Med. 2022 Apr 18;20(1):118. doi: 10.1186/s12916-022-02319-y, PMID 35430795, PMCID PMC9014562
19. Yi F, Xu B, Diao S, Hou C, Li JY. Population-based study of the effects of adiponectin, leptin and soluble leptin receptor on risks for breast cancer. Sichuan Da Xue Xue Bao Yi Xue Ban. 2021 Mar;52(2):259-66. doi: 10.12182/20210260302, PMID 33829700, PMCID PMC10408924
20. Vallega KA, Liu N, Myers JS, Yu K, Sang QX. Elevated resistin gene expression in African American estrogen and progesterone receptor negative breast cancer. PLOS One. 2016;11(6):e0157741. doi: 10.1371/ journal.pone.0157741, PMID 27314854
21. Savulescu-Fiedler I, Mihalcea R, Dragosloveanu S, Scheau C, Baz RO, Caruntu A, et al. The interplay between obesity and inflammation. Life (Basel). 2024 Jul 8;14(7):856. doi: 10.3390/life14070856, PMID 39063610, PMCID PMC11277997
22. Peraldi P, Loubat A, Chignon-Sicard B, Dani C, Ladoux A. Identification of human breast adipose tissue progenitors displaying distinct differentiation potentials and interactions with cancer cells. Biomedicines. 2022 Aug 9;10(8):1928. doi: 10.3390/ biomedicines10081928, PMID 36009475, PMCID PMC9406003
23. Lee EY, Lee DW, Lee KH, Im SA. Recent developments in the therapeutic landscape of advanced or metastatic hormone receptor-positive breast cancer. Cancer Res Treat. 2023 Oct 5;55(4):1065-76. doi: 10.4143/crt.2023.846, PMID 37817306
24. García-Estevez L, González-Martínez S, Moreno-Bueno G. The leptin axis and its association with the adaptive immune system in breast cancer. Front Immunol. 2021 Nov 15;12:784823. doi: 10.3389/ fimmu.2021.784823, PMID 34868066, PMCID PMC8634160
25. Naimo GD, Forestiero M, Paolì A, Malivindi R, Gelsomino L, Győrffy B, et al. ERα/LKB1 complex upregulates E‐cadherin expression and stimulates breast cancer growth and progression upon adiponectin exposure. Int J Cancer. 2023 Sep 15;153(6):1257-72. doi: 10.1002/ijc.34626, PMID 37323038
26. Lee E, Ouzounova M, Piranlioglu R, Ma MT, Guzel M, Marasco D, et al. The pleiotropic effects of TNFα in breast cancer subtypes is regulated by TNFAIP3/A20. Oncogene. 2019 Jan;38(4):469-82. doi: 10.1038/s41388-018-0472-0, 2018 Aug 30. Erratum in: Oncogene. 2019 Jul;38(28):5749. doi: 10.1038/s41388-019-0838-y, PMID 31197211, PMCID PMC6602794
27. Mahmoud WS, Azmy OM, Abu-Elghait M, Gomaa MM, El Sayed IE, Hammad DY, et al. Metabolic syndrome as independent risk factor among sample of Egyptian women with breast cancer. Bull Natl Res Cent. 2022;46(1):246. doi: 10.1186/s42269-022-00962-2
28. Contreras-García CE, Guizar-García LA, Noyola-García ME, Anda-Garay JC. Asociación Entre síndromemetabólico y cáncer de mama [Association between metabolic syndrome and breast cancer]. Rev Med Inst Mex Seguro Soc. 2020 Apr 27;58 Supl 1:S97-S103. [Spanish]. doi: 10.24875/RMIMSS.M20000120, PMID 34695321
29. Krupa-Kotara K, Dakowska D. Impact of obesity on risk of cancer. Cent Eur J Public Health. 2021 Mar;29(1):38-44. doi: 10.21101/cejph. a5913, PMID 33831285
30. Hao Y, Jiang M, Miao Y, Li X, Hou C, Zhang X, et al. Effect of long-term weight gain on the risk of breast cancer across women’s whole adulthood as well as hormone-changed menopause stages: A systematic review and dose-response meta-analysis. Obes Res Clin Pract. 2021 Sep-Oct;15(5):439-48. doi: 10.1016/j.orcp.2021.08.004, PMID 34456166
31. Ademi-Islami D, Manxhuka-Kerliu S, Tarifa-Koroveshi D, Koliqi R, Mujaj B. Metabolic syndrome and breast cancer molecular subtypes: An observational patient study. Breast Cancer (Auckl). 2022 Mar 23;16:11782234221080555. doi: 10.1177/11782234221080555, PMID 35340887, PMCID PMC8950023
32. Tsankof A, Tziomalos K. Adiponectin: A player in the pathogenesis of hormone-dependent cancers. Front Endocrinol (Lausanne). 2022 Oct 6;13:1018515. doi: 10.3389/fendo.2022.1018515, PMID 36277714, PMCID PMC9582436
33. Babaei Z, Parsian H, Korani B, Mostafazadeh A, Moslemi D. Body composition and serum levels of matrix metalloproteinase-9, adiponectin and AMP-activated protein kinase in breast cancer survivors. J Res Med Sci. 2022 Jun 30;27:48. doi: 10.4103/jrms. JRMS_453_20, PMID 35968203, PMCID PMC9374150
34. Yu Z, Tang S, Ma H, Duan H, Zeng Y. Association of serum adiponectin with breast cancer: A meta-analysis of 27 case-control studies. Med (Baltim). 2019 Feb;98(6):e14359. doi: 10.1097/ MD.0000000000014359, PMID 30732167, PMCID PMC6380750
35. Danthala M, Rajesh GR, Gundeti S, Raju GS, Chandran P, Srinivas ML. Obesity and breast cancer: association of serum adiponectin, leptin, and adiponectin-leptin ratio as risk biomarkers. Indian J Med Paediatr Oncol. 2018;39(3):292-6. doi: 10.4103/ijmpo.ijmpo_203_16
36. Mohanty SS, Mohanty PK. Obesity as potential breast cancer risk factor for postmenopausal women. Genes Dis. 2021;8(2):117-23. doi: 10.1016/j.gendis.2019.09.006, PMID 33997158, PMCID PMC8099684
37. Bhardwaj P, Au CC, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R, et al. Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019 May;189:161-70. doi: 10.1016/j.jsbmb.2019.03.002, PMID 30851382, PMCID PMC6502693
38. Vatier C, Antuna-Puente B, Fellahi S, Vigouroux C, Capeau J, Bastard JP. Groupe de travail RIHN adipokines. Le rapport adiponectinesurleptine, unbiomarqueurd’insulino-résistance et de risquecardiométabolique encore méconnu [The adiponectin to leptin ratio, a still unrecognized biomarker of insulin resistance and cardiometabolic risk]. Ann Biol Clin (Paris). 2020 Jun 1;78(3):265-8. [French]. doi: 10.1684/abc.2020.1559, PMID 32420886
39. Akinyemiju T, Oyekunle T, Salako O, Gupta A, Alatise O, Ogun G, et al. Metabolic syndrome and risk of breast cancer by molecular subtype: analysis of the MEND study. Clin Breast Cancer. 2022 Jun;22(4):e463-72. doi: 10.1016/j.clbc.2021.11.004, 2021 Nov 23. PMID 34980540, PMCID PMC9641637
40. Assiri AM, Kamel HF, Hassanien MF. Resistin, visfatin, adiponectin, and leptin: Risk of breast cancer in pre- and postmenopausal Saudi females and their possible diagnostic and predictive implications as novel biomarkers. Dis Markers. 2015;2015:253519. doi: 10.1155/2015/253519, PMID 25838618
41. Bocian-Jastrzębska A, Malczewska-Herman A, Kos-Kudła B. Role of leptin and adiponectin in carcinogenesis. Cancers (Basel). 2023 Aug 24;15(17):4250. doi: 10.3390/cancers15174250, PMID 37686525, PMCID PMC10486522
42. Vliora M, Ravelli C, Grillo E, Corsini M, Flouris AD, Mitola S. The impact of adipokines on vascular networks in adipose tissue. Cytokine Growth Factor Rev. 2023 Feb;69:61-72. doi: 10.1016/j. cytogfr.2022.07.008, PMID 35953434
43. Kim DS, Scherer PE. Obesity, diabetes, and increased cancer progression. Diabetes Metab J. 2021 Nov;45(6):799-812. doi: 10.4093/ dmj.2021.0077, PMID 34847640, PMCID PMC8640143
44. Incio J, Ligibel JA, McManus DT, Suboj P, Jung K, Kawaguchi K, et al. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci Transl Med. 2018 Mar 14;10(432):eaag0945. doi: 10.1126/scitranslmed.aag0945, PMID 29540614, PMCID PMC5936748
45. Lagarde CB, Thapa K, Cullen NM, Hawes ML, Salim K, Benz MC, et al. Obesity and leptin in breast cancer angiogenesis. Front Endocrinol (Lausanne). 2024 Oct 8;15:1465727. doi: 10.3389/fendo.2024.1465727, PMID 39439572, PMCID PMC11493622
46. Deshmukh SK, Srivastava SK, Poosarla T, Dyess DL, Holliday NP, Singh AP, et al. Inflammation, immunosuppressive microenvironment and breast cancer: Opportunities for cancer prevention and therapy. Ann Transl Med. 2019 Oct;7(20):593. doi: 10.21037/atm.2019.09.68, PMID 31807574, PMCID PMC686174947. Kumar A. Comprehensive review on etiopathogenesis, treatment and emerging therapies of breast cancer. Asian J Pharm Clin Res. 2021;14(8):20-33. doi: 10.22159/ajpcr.2021.v14i8.41974
48. Marsh ML, Oliveira MN, Vieira-Potter VJ. Adipocyte metabolism and health after the menopause: The role of exercise. Nutrients. 2023 Jan 14;15(2):444. doi: 10.3390/nu15020444, PMID 36678314, PMCID PMC9862030
49. Wang YY, Hung AC, Lo S, Yuan SF. Adipocytokines visfatin and resistin in breast cancer: clinical relevance, biological mechanisms, and therapeutic potential. Cancer Lett. 2021 Feb 1;498:229-39. doi: 10.1016/j.canlet.2020.10.045, PMID 33152400
50. Bastard JP, Dridi-Brahimi I, Vatier C, Fellahi S, Fève B. Biological markers of adipose tissue: adipokines. Ann Endocrinol (Paris). 2024 Jun;85(3):171-2. doi: 10.1016/j.ando.2024.04.002, PMID 38614158
51. Barrios CH. Global challenges in breast cancer detection and treatment. Breast. 2022 Mar;62 Suppl 1(Suppl 1):S3-6. doi: 10.1016/j. breast.2022.02.003, PMID 35219542, PMCID PMC9097801
Published
How to Cite
Issue
Section
Copyright (c) 2025 Deepthi Enumula
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
